Last Updated : December 18, 2015
Details
FilesGeneric Name:
Lenalidomide
Project Status:
Complete
Therapeutic Area:
Multiple Myeloma, newly diagnosed
Manufacturer:
Celgene Inc.
Brand Name:
Revlimid
Project Line:
Reimbursement Review
Project Number:
PC0061-000
Performance Metric:
Achieved
Strength:
5, 10, 15, 25 mg capsules
Tumour Type:
Myeloma
Indications:
Multiple Myeloma (newly diagnosed)
Funding Request:
In combination with low-dose dexamethasone, for treatment of newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Celgene Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : December 18, 2015